An example of a noncontrast MRA image from Toshiba.


February 26, 2010 - Gadolinium-based contrast agents, the most common contrast agents used for MRA, have been directly linked to nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD) a sometimes fatal skin disease that occurs in patients with renal insufficiency.

In response to concern over gadolinium-based contrast agents, Little Company of Mary, a nonprofit Catholic community hospital in Evergreen Park, Ill., wanted to provide the highest quality and safest MRA procedures to its patients.

To accomplish this, the facility installed a magnetic resonance imaging (MRI) system the is capable of using contrast-free MRA techniques. These contrast-free techniques allowed Little Company of Mary to now complete 98 percent of its MRA exams without contrast.

The organization acquired a Vantage Atlas MR unit by Toshiba America Medical Systems Inc. The manufacturer developed the full suite of contrast-free MRA techniques available on the entire Vantage MR product line to combat adverse medical events such as NSF/NFD. These techniques include fresh blood imaging (FBI), contrast-free tmproved angiography (CIA), time-spatial labeling inversion pulse (time-SLIP) and time and space angiography (TSA).

The system also enables the hospital to improve hospital efficiency. For example, by not using contrast the team has reduced the need for rescans that sometimes occurs when a bolus is missed, and they also do not need to run pre-exam lab tests on patients to evaluate renal function.

For more information: www.nocontrast.com


Related Content

News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 23, 2024 — Researchers at the National Institutes of Health (NIH) found that an artificial intelligence (AI) model ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 17, 2024 — Hyperfine, a groundbreaking medical device company that has redefined brain imaging with the world’s ...

Time July 17, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 2, 2024 — A new editorial paper was published in Oncoscience (Volume 11) on May 20, 2024, entitled, “Deep learning ...

Time July 02, 2024
arrow
Subscribe Now